The FDA approved osimertinib as first-line treatment for NSCLC carrying EGFR exon 19 deletion or exon 21 L858R mutation in April 2018 after comparing the efficacy of osimertinib with standard treatment through the FLAURA trial (Tatineni et al. 2023; Kim et al. 2009). This evidence concerns the gene EGFR and non-small cell lung carcinoma.